Caleco Pharma Corp. Watch

from 8-K 4 pages Investor Relations Consulting Agreement

from 10-Q 2 pages Public Relations, Promotion and Marketing Letter Agreement Dated August 12, 2010

from 8-K 2 pages Third Amendment Agreement to Lab Facilities and Services Agreement

from 8-K 5 pages Management Consulting Agreement

from 8-K 2 pages Second Amendment Agreement to Lab Facilities and Services Agreement

from 8-K 2 pages Second Amendment Agreement to Share Purchase Agreement

from 8-K 2 pages Amendment Agreement to Lab Facilities and Services Agreement This Agreement Is Dated the 19th Day of March, 2010. Between: Natac Biotech, S.L., a Spanish Corporation Having an Address at Calle Ana De Austria, 28660 Boadilla Del Monte, Madrid, Spain (Hereinafter Called "Natac") of the First Part And: Caleco Pharma Corp., a Nevada Corporation Having an Address at Suite 410 – 103 East Holly Street, National Bank Building, Bellingham, Wa 98225. (Hereinafter Called "Caleco") of the Second Part Whereas

from 8-K 2 pages Amendment Agreement to Share Purchase Agreement This Agreement Is Dated the 19th Day of March, 2010. Between: Natac Biotech, S.L., a Spanish Corporation Having an Address at Calle Ana De Austria, 28660 Boadilla Del Monte, Madrid, Spain (Hereinafter Called "Natac") of the First Part And: Antonio Delgado Romero, an Individual Having an Address at Calle Manuel De Falla 4a, 05260 Avila, Spain. (Hereinafter Called "Romero") of the Second Part And: Jose Carlos Quintela Fernandez, an Individual Having an Address at Calle Tellez 28007, Madrid, Spain. (Hereinafter Called "Fernandez") of the Third Part And: Caleco Pharma Corp., a Nevada Corporation Having an Address at Suite 410 – 103 East Holly Street, National Bank Building, Bellingham, Wa 98225. (Hereinafter Called "Caleco") of the Fourth Part Whereas

from 10-Q 13 pages Exclusive License Agreement

from 8-K 9 pages Lab Facilities and Service Agreement

from 8-K 1 page Promissory Note Executed By: Caleco Pharma Corp. (The "Payor") in Favor Of: Natac Biotech S.L. (The "Payee") Principal Amount: Eur 130,000 for Value Received the Payor Hereby Promises to Pay to or to the Order of the Payee the Principal Sum of 130,000 Euros, Without Interest on March 19, 2010. the Payor Waives Presentment, Demand, Notice, Protest and Notice of Dishonor and All Other Demands and Notices in Connection With the Delivery, Acceptance, Performance, Default or Enforcement of This Promissory Note

from 8-K 2 pages February 10, 2010 Natac Biotech S.L. Calle Ana De Austria 7 Ptl 2 – 2d Boadilla Del Monte (Madrid), Spain Attention: Antonio Delgado Romero Dear Sirs: Re: Lab Facilities and Services Agreement Caleco Pharma Corp. (The “Company”) and Natac Biotech S.L. (“Natac”) Are in the Process of Negotiating a Lab Facilities and Services Agreement Whereby Natac Will Provide the Company With Access to a Laboratory Facility and Certain Laboratory Services (The “Proposed Agreement”). 1. Exclusivity 1.1 Natac Agrees That, During a 60 Day Period From Execution of This Letter Agreement, It Will Not Seek or Solicit, or Engage Anyone to Seek or Solicit, or Negotiate With Other Suitors to Enter Into a Lab Facilities and Services Agreement (The “Exclusive Period”). 2. Consideration 2.1 in Consideration of the Exclusive Period, the Company Has Agreed To: (A) Pay 20,000 Euros on Execution of This Letter Agreement (The “Payment”); and (B) Issue to Natac a Non-Interest Bearing Promissory Note in the Amount of 130,000 Euros (The “Promissory Note”), Payable Within Thirty Days of This Letter Agreement. 2.2 if Natac and Caleco Enter Into the Proposed Agreement, Natac Shall Apply the Payment and Any Payments Under the Promissory Note to the Amounts to Be Paid Under the Proposed Agreement. 2.3 in the Event That Natac and Caleco Are Unable to Enter Into the Proposed Agreement Within Sixty Days of This Letter Agreement, Natac Will Retain the Payment and Any Payments Made Under the Promissory Note, as a Compensation for the Assessment and Consulting During the Negotiation Period. 3. Executed in Counterparts 3.1 This Letter Agreement May Be Executed in One or More Counterparts, Each of Which So Executed Shall Constitute an Original and All of Which Together Shall Constitute One and the Same Letter Agreement

from 8-K 8 pages Share Purchase Agreement

from 8-K 5 pages Designated Sponsor Agreement

from 8-K 3 pages Consulting Agreement

from 8-K 3 pages Consulting Agreement

from 8-K 15 pages Exclusive License Agreement

from 8-K 12 pages Consulting Agreement October 27th, 2009

from 8-K 5 pages This Service Agreement Is Entered Into on 10/06/09 (Herein the "Effective Date") Between Evergreen Marketing, Inc. and Caleco Pharma Corp. for Shareholder Awareness Services Related to Caleco Pharma Corp.(otcbb: Caeh). Caleco Pharma Corp. Herein May Be Referred to as “Client.” A. Evergreen Marketing, Inc. Provides Consulting and Marketing Services in Connection With Client’s Ongoing Business Activities. B. Client Employs the Services of Evergreen Marketing, Inc. to Provide Consulting and Marketing Services, as Defined Below, and Evergreen Marketing, Inc. to Provide Such Services to Client. Now, Therefore, for the Mutual Promises, Representations, Warranties and Covenants Contained Herein, the Parties Agree as Follows: Agreement 1. Consulting and Marketing Services. Evergreen Marketing, Inc. Shall Provide the Following Services Throughout the Term of This Agreement (Collectively the "Consulting and Marketing Services”): 1.1 Corporate Consulting and Promotion Including, but Not Limited To, E-Mail Database Distribution and at Least Two (2) Taped Green Baron CEO Webcasts Available at WWW.THEGREENBARON.com

from 8-K 2 pages Promissory Note